Cartesian Therapeutics, Inc. (RNAC) Stock Grade

About Cartesian Therapeutics, Inc.'s fundamentals

Cartesian Therapeutics is a small-cap biotechnology company with a market capitalization of $187.3 million that reported a significant net loss in its latest annual statement, reflected in an extremely negative net margin of -4658.6%. Revenue contracted sharply year-over-year by 92.8%, indicating substantial operational challenges. The company does not pay a dividend and lacks a meaningful P/E ratio due to its unprofitability. While the return on equity figure of 103.2% appears positive, it should be interpreted cautiously given the company's loss-making status and likely reflects accounting effects rather than sustainable earnings power.